Telomir Pharmaceuticals Mourns the Passing of Chairman and CEO Dr. Christopher Chapman
12 August 2024 - 10:30PM
Telomir Pharmaceuticals, Inc. (Nasdaq:
TELO) (“Telomir” or the “Company”), a pre-clinical-stage
pharmaceutical company focused on the development and
commercialization of Telomir-1 to promote longevity in humans and
dogs through the treatment of age-related conditions, today
announced the passing of Chairman of the Board and Chief Executive
Officer Christopher Chapman, Jr., M.D. Out of respect and privacy
for Dr. Chapman’s family, details of his passing will not be made
available.
Telomir’s Board of Directors has named Erez
Aminov, currently Chairman of the Board and Chief Executive Officer
of MIRA Pharmaceuticals, Inc. (Nasdaq: MIRA), as a director,
Chairman of the Board and Chief Executive Officer of
Telomir.
To offer support to Telomir’s new senior
management, three Telomir directors have voluntarily resigned from
the Telomir Board of Directors, and three individuals have been
appointed as replacements. The new Telomir directors are Dr.
Matthew P. Del Giudice, Mr. Ned MacPherson and Matthew Pratt
Whalen, CPA. Dr. Craig Eagle and Michael Jerman, each sitting
directors of Telomir, will remain on the Telomir Board of
Directors. The resigning directors are Hugh McColl III, Talhia Tuck
and Brad Kroenig.
Dr. Craig Eagle, an independent member of
Telomir’s Board of Directors, stated: “The entire Telomir community
is devastated by the loss of Dr. Chapman. Not only was he a
founding officer and director of Telomir, but he was a leading
scientist and researcher as well as a kind and decent man. Our
thoughts and thanks go out to Dr. Chapman’s family. We are also
grateful to Erez for joining our company to fill these important
roles as Telomir continues to progress its business.”
Mr. Aminov stated, “Dr. Chapman’s passion for
the potential of Telomir-1 is inspiring, and I hope to carry on
with his work with that same passion. I appreciate the trust that
the Telomir board has placed in me at this challenging time. I look
forward to working with Telomir and moving its promising drug
candidate forward.”
About Telomir
Pharmaceuticals, Inc.
Telomir Pharmaceuticals, Inc. (Nasdaq:TELO) is a
pre-clinical-stage pharmaceutical company focused on the
development and commercialization of Telomir-1 as the first novel
small molecule to lengthen the DNA’s protective telomere caps in
order to potentially promote longevity in humans and dogs through
the treatment of age-related conditions. Telomeres are the
protective end caps of a chromosome made up of DNA sequences and
proteins. As humans age, telomeres shorten, with metal reactivity
accelerating the process, which presents us with an increased
chance of contracting a number of degenerative and age-related
diseases. Telomir’s goal is to develop and commercialize Telomir-1,
proposed to be dosed orally, with the broader aim of promoting
longevity and enhancing overall quality of life. The Nobel Assembly
at Karolinska Institute (Sweden) awarded the Nobel Prize in
Physiology or Medicine in 2009 for the discovery of how chromosomes
are protected by telomeres and the enzyme telomerase.
Cautionary Note Regarding
Forward-Looking Statements
This press release contains forward-looking
statements, including statements made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
These statements may be identified by words such as "aims,"
"anticipates," "believes," "could," "estimates," "expects,"
"forecasts," "goal," "intends," "may," "plans," "possible,"
"potential," "seeks," "will," and variations of these words or
similar expressions that are intended to identify forward-looking
statements. Any such statements in this press release that are not
statements of historical fact may be deemed to be forward-looking
statements. These forward-looking statements include, without
limitation, statements regarding the appointment of Mr. Aminov to
his positions with the Company.
Any forward-looking statements in this press
release are based on Telomir's current expectations, estimates and
projections only as of the date of this release and are subject to
a number of risks and uncertainties that could cause actual results
to differ materially and adversely from those set forth in or
implied by such forward-looking statements. These risks and
uncertainties include, but are not limited to, the potential use of
the data from our studies, our ability to develop and commercialize
Telomir-1 and the aging process and safety of Telomir-1 . These and
other risks concerning Telomir's programs and operations are
described in additional detail in its Annual Report on Form 10-K
for the fiscal year ended December 31, 2023, which is on file with
the SEC. Telomir explicitly disclaims any obligation to update
any forward-looking statements except to the extent required by
law.
For further information, please contact:
Telomir Pharmaceuticalsinfo@Telomirpharma.com(813) 864-2558
Telomir Pharmaceuticals (NASDAQ:TELO)
Historical Stock Chart
From Jul 2024 to Aug 2024
Telomir Pharmaceuticals (NASDAQ:TELO)
Historical Stock Chart
From Aug 2023 to Aug 2024